- KR₩2tn
- KR₩2tn
- KR₩274bn
- 46
- 11
- 24
- 13
Annual balance sheet for ST Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 140,636 | 93,216 | 50,201 | 90,097 | 120,924 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 46,762 | 64,448 | 97,871 | 122,627 | 69,976 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 235,613 | 244,142 | 263,234 | 348,378 | 330,078 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 175,634 | 210,190 | 257,885 | 280,105 | 338,695 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 445,570 | 498,565 | 570,652 | 675,436 | 721,876 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 18,610 | 75,365 | 179,224 | 83,745 | 133,281 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 150,242 | 175,591 | 233,020 | 290,886 | 218,743 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 295,328 | 322,974 | 337,632 | 384,550 | 503,132 |
Total Liabilities & Shareholders' Equity | 445,570 | 498,565 | 570,652 | 675,436 | 721,876 |
Total Common Shares Outstanding |